Loading…
Chinese company classified under health care/biotechnology; specific business segments not established from available knowledge.
Chinese company classified under health care/biotechnology; specific business segments not established from available knowledge.
Moat: none
Headquarters: China · Employees: 2,755
Size Pacific Shuanglin Bio-pharmacy (000403.SZ) is a China Health Care company (Biotechnology) with a market value of $1.38B, the 1768th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥9.72 on 6 Nov 2026.
Performance Over six months the shares fell 18.7%, against -20.9% for the median peer and -16.4% for the China market (cap-weighted) — 10th highest of 20 in its peer set.
Growth Revenue grew 1.5% over the last twelve months (peer median +16.6%); the operating margin is 9.7% (peer median -44.2%).
Valuation It trades at 29.4× forward earnings against a peer median of 27.0× (4th most expensive of 8).
Capital Return on invested capital runs 1.6 points below its cost of capital (5.0% WACC).
Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥2.42B | CN¥2.62B | CN¥2.64B | CN¥2.32B | CN¥2.39B |
| Revenue growth | — | -1% | +14% | -3% | — |
| Gross profit | CN¥895M | CN¥1.04B | CN¥1.26B | CN¥1.15B | CN¥1.20B |
| EBITDA | n/a | CN¥715M | CN¥929M | CN¥781M | CN¥716M |
| Net income | CN¥212M | CN¥419M | CN¥745M | CN¥612M | CN¥587M |
| Free cash flow | -CN¥164M | -CN¥478M | -CN¥109M | CN¥379M | CN¥190M |
| Capital expenditure | CN¥226M | CN¥333M | CN¥521M | CN¥377M | CN¥379M |
| Total debt | CN¥1.06B | CN¥829M | CN¥672M | CN¥503M | CN¥407M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 000403.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.2% | -2.0% | 10th highest of 21 |
| 6-month return | -18.7% | -20.9% | 10th highest of 20 |
| Distance from 52-week high | -40.8% | -41.6% | 11th highest of 21 |
| Revenue growth (TTM) | +1.5% | +16.6% | 7th lowest of 16 |
| Operating margin | 9.7% | -44.2% | 6th highest of 15 |
| Forward P/E | 29.4× | 27.0× | 4th most expensive of 8 |
| ROIC minus cost of capital | -1.6 pp | -4.4 pp | 5th highest of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Pacific Shuanglin Bio-pharmacy 000403.SZ | China | $1.38B | -19% | +1% | 10% | 29.4× | n/a | n/a |
| Oncolys BioPharma 4588.T | Japan | $1.39B | +162% | +1,662% | -303% | n/a | n/a | n/a |
| AnaptysBio ANAB | United States | $1.39B | -33% | +93% | 56% | 8.6× | -1.2% | +25.6% |
| Hualan Biological Vaccine 301207.SZ | China | $1.39B | -21% | -28% | -7% | 42.8× | 36.5% | -13.1% |
| Mineralys Therapeutics MLYS | United States | $1.36B | -48% | n/a | n/a | n/a | n/a | n/a |
| Taysha Gene Therapies TSHA | United States | $1.41B | -36% | -32% | -2,855% | n/a | n/a | n/a |
| Korsana Biosciences KRSA | United States | $1.41B | +43% | -13% | -359% | n/a | n/a | n/a |
| Kardigan KARD | United States | $1.45B | n/a | n/a | n/a | n/a | n/a | n/a |
| Tyra Bioscience TYRA | United States | $1.45B | -38% | n/a | n/a | n/a | n/a | n/a |
| Nuvation Bio NUVB | United States | $1.46B | -13% | +1,084% | -81% | n/a | n/a | n/a |
| Liaoning Chengda Biotechnology 688739.SS | China | $1.28B | -10% | -9% | 0% | 46.2× | 8.8% | -7.0% |
| PELL Bio-Med Technology 6949.TW | Taiwan | $1.49B | +126% | +5% | -1,720% | n/a | n/a | n/a |
| uniQure QURE | United States | $1.51B | -22% | +30% | -1,093% | n/a | n/a | n/a |
| Hugel 145020.KS | South Korea | $1.52B | -26% | +17% | 38% | 15.7× | -7.9% | +15.0% |
| Fujian Haixi Pharmaceuticals 2637.HK | Hong Kong | $1.53B | -41% | +25% | 33% | 48.2× | n/a | n/a |
| Inhibrx Biosciences INBX | United States | $1.24B | -37% | -100% | n/a | n/a | n/a | n/a |
| SpyGlass Pharma SGP | United States | $1.24B | +58% | n/a | n/a | n/a | n/a | n/a |
| ANI Pharmaceuticals ANIP | United States | $1.55B | -18% | +31% | 13% | 7.6× | -4.1% | +33.5% |
| Duality Biotherapeutics 9606.HK | Hong Kong | $1.23B | -60% | -5% | -181% | n/a | n/a | n/a |
| Akums Drugs and Pharmaceuticals AKUMS.NS | India | $1.22B | +34% | +18% | 10% | 27.0× | 15.8% | +9.9% |
| Vor Biopharma VOR | United States | $1.22B | +17% | n/a | n/a | n/a | n/a | n/a |